{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:33:36Z","timestamp":1790393616182,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.tranon.2021.101079","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T09:47:21Z","timestamp":1618480041000},"page":"101079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Novel antigens of CAR T cell therapy: New roads; old destination"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9901-7851","authenticated-orcid":false,"given":"Pooria","family":"Safarzadeh Kozani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.tranon.2021.101079_bib0001","first-page":"842","article-title":"Paul Ehrlich (1854-1915): man with the magic bullet","volume":"51","author":"Tan","year":"2010","journal-title":"Singap. Med. J."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"Tisagenlecleucel\u2014The first approved CAR-T-cell therapy: implications for payers and policy makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101079_bib0003","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.tranon.2021.101079_bib0004","first-page":"832","article-title":"CAR-T Therapy Is Approved for Mantle Cell Lymphoma","volume":"324","author":"Voelker","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.tranon.2021.101079_bib0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12032-020-01416-3","article-title":"Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia","volume":"37","author":"Hashem Boroojerdi","year":"2020","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-021-00031-9","article-title":"FDA approves fourth CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2021.101079_bib0007","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"6449","key":"10.1016\/j.tranon.2021.101079_bib0008","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"issue":"6476","key":"10.1016\/j.tranon.2021.101079_bib0009","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of Claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.tranon.2021.101079_bib0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.tranon.2021.101079_bib0011","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2021.101079_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109625","article-title":"PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges","volume":"121","author":"McGowan","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"15","key":"10.1016\/j.tranon.2021.101079_bib0014","article-title":"Phase I Alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL","volume":"38","author":"Osborne","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7749","key":"10.1016\/j.tranon.2021.101079_bib0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101079_bib0016","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.tranon.2021.101079_bib0017","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J. Immunother."},{"issue":"14","key":"10.1016\/j.tranon.2021.101079_bib0018","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.tranon.2021.101079_bib0019","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0020","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0023","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.tranon.2021.101079_bib0024","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","article-title":"IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors","volume":"28","author":"Giuffrida","year":"2020","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-140120","article-title":"High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in vivo CAR T-cell kinetics","volume":"136","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"6379","key":"10.1016\/j.tranon.2021.101079_bib0026","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0027","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.tranon.2021.101079_bib0028","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.217.217","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.tranon.2021.101079_bib0029","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0030","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2021.101079_bib0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","article-title":"CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs","volume":"141","author":"Rahbarizadeh","year":"2019","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"2","key":"10.1016\/j.tranon.2021.101079_bib0032","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","article-title":"Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents","volume":"334","author":"Sharifzadeh","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0033","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbagen.2013.09.029","article-title":"T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy","volume":"1840","author":"Jamnani","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0034","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-012-1037-6","article-title":"A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells","volume":"95","author":"Khaleghi","year":"2012","journal-title":"Int. J. Hematol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0035","first-page":"502","article-title":"A VHH-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells","volume":"22","author":"Rajabzadeh","year":"2021","journal-title":"Cell J."},{"issue":"18","key":"10.1016\/j.tranon.2021.101079_bib0036","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.yexcr.2011.08.015","article-title":"Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by \u03c6C31 integrase","volume":"317","author":"Iri-Sofla","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.tranon.2021.101079_bib0037","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/hyb.2008.0079","article-title":"Anti-MUC1 nanobody can redirect T-body cytotoxic effector function","volume":"28","author":"Bakhtiari","year":"2009","journal-title":"Hybridoma (Larchmt)"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0038","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.tranon.2021.101079_bib0039","article-title":"PLAP (placental alkaline phosphatase)-CAR-T cells specifically target colorectal cancer","volume":"80","author":"Golubovskaya","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2021.101079_bib0040","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2741\/4877","article-title":"PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells","volume":"25","author":"Li","year":"2020","journal-title":"Front. Biosci. (Landmark Ed)"},{"issue":"15","key":"10.1016\/j.tranon.2021.101079_bib0041","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.tranon.2021.101079_bib0042","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.115.115","article-title":"CAR-engineered T cells specific for the Elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets","volume":"126","author":"Danhof","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.tranon.2021.101079_bib0043","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0044","article-title":"Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma","volume":"130","author":"Mathur","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0046","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2021.101079_bib0047","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","author":"Amatya","year":"2020","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0048","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.tranon.2021.101079_bib0049","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.tranon.2021.101079_bib0051","article-title":"Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma","volume":"37","author":"Zhan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101079_bib0052","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/dvdy.1174","article-title":"Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium","volume":"222","author":"Turksen","year":"2001","journal-title":"Dev. Dyn."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0053","doi-asserted-by":"crossref","first-page":"16735","DOI":"10.1038\/s41598-019-53130-4","article-title":"Author correction: targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0054","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0055","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.V99.1.310","article-title":"FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model","volume":"99","author":"Kelly","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2021.101079_bib0056","doi-asserted-by":"crossref","first-page":"e25351","DOI":"10.1371\/journal.pone.0025351","article-title":"Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells","volume":"6","author":"Weisberg","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0057","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041537","article-title":"Overcoming resistance to FLT3 inhibitors in the treatment of FLT3-mutated AML","volume":"21","author":"Lam","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.tranon.2021.101079_bib0059","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135306","article-title":"Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell","volume":"4","author":"He","year":"2019","journal-title":"JCI Insight"},{"issue":"18","key":"10.1016\/j.tranon.2021.101079_bib0060","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.tranon.2021.101079_bib0061","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0062","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2021.101079_bib0063","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","article-title":"Improving the safety of cell therapy products by suicide gene transfer","volume":"5","author":"Jones","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.tranon.2021.101079_bib0064","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101079_bib0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.tranon.2021.101079_bib0066","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","article-title":"Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation","volume":"107","author":"Berger","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0067","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0068","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0069","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2019.12.014","article-title":"An optimized full-length FLT3\/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity","volume":"28","author":"Yeung","year":"2020","journal-title":"Mol. Ther."},{"issue":"15","key":"10.1016\/j.tranon.2021.101079_bib0070","article-title":"First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory ACUTE lymphoblastic leukemia\/lymphoma","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0071","article-title":"111\u2005Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL","volume":"8","author":"Gehrke","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0072","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0073","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/j.bbmt.2019.12.482","article-title":"CD5 CAR T-cells for treatment of patients with relapsed\/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity","volume":"26","author":"Hill","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0074","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/eji.201948309","article-title":"CD5 blockade enhances ex vivo CD8(+) T cell activation and tumour cell cytotoxicity","volume":"50","author":"Alotaibi","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0075","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1038\/s41467-019-12824-z","article-title":"B-1a cells acquire their unique characteristics by bypassing the pre-BCR selection stage","volume":"10","author":"Wong","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.tranon.2021.101079_bib0076","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.20011140","article-title":"B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen","volume":"195","author":"Wardemann","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101079_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0078","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/08923973.2019.1637889","article-title":"T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide","volume":"41","author":"Zhou","year":"2019","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.tranon.2021.101079_bib0079","article-title":"A novel chimeric antigen receptor redirecting T-cell specificity towards CD26(+) cancer cells","author":"Zhou","year":"2020","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.tranon.2021.101079_bib0080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138808","article-title":"CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth","volume":"5","author":"Zhuang","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0081","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/onc.2011.233","article-title":"Identification and angiogenic role of the novel tumor endothelial marker CLEC14A","volume":"31","author":"Mura","year":"2012","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0082","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/onc.2011.233","article-title":"Identification and angiogenic role of the novel tumor endothelial marker CLEC14A","volume":"31","author":"Mura","year":"2012","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.tranon.2021.101079_bib0083","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1152\/physiolgenomics.90201.2008","article-title":"Serial analysis of the vascular endothelial transcriptome under static and shear stress conditions","volume":"34","author":"Chu","year":"2008","journal-title":"Physiol. Genom."},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0084","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/gt.2013.19","article-title":"Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency","volume":"20","author":"Wang","year":"2013","journal-title":"Gene Ther."},{"issue":"11","key":"10.1016\/j.tranon.2021.101079_bib0085","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0086","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/ijc.28269","article-title":"Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery","volume":"133","author":"Fu","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0087","article-title":"Abstract A16: a GUCY2c-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors","volume":"8","author":"Mathur","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0088","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1227897","article-title":"GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity","volume":"5","author":"Magee","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0089","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/2326-6066.CIR-16-0362","article-title":"Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases","volume":"6","author":"Magee","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0090","article-title":"105\u2005A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy","volume":"8","author":"Baybutt","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2021.101079_bib0091","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","article-title":"TEM8\/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer","volume":"78","author":"Byrd","year":"2018","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.tranon.2021.101079_bib0092","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224015","article-title":"TEM8\/ANTXR1-specific CAR T cells mediate toxicity in vivo","volume":"14","author":"Petrovic","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0093","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1002\/jcb.27776","article-title":"MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma","volume":"120","author":"Sotoudeh","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.tranon.2021.101079_bib0094","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091971","article-title":"Podoplanin as an attractive target of CAR T cell therapy","volume":"9","author":"Waseda","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","article-title":"CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains","volume":"4","author":"Shiina","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tranon.2021.101079_bib0096","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1038\/srep05924","article-title":"A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin","volume":"4","author":"Kato","year":"2014","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.tranon.2021.101079_bib0097","article-title":"Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors","volume":"80","author":"Levitsky","year":"2020","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2021.101079_bib0098","first-page":"vi552","article-title":"A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)","volume":"27","author":"Sachdev","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0099","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1084\/jem.194.1.13","article-title":"Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin","volume":"194","author":"Doyonnas","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101079_bib0100","article-title":"A cancer-specific anti-podocalyxin monoclonal antibody (60-mG(2a)-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma","volume":"24","author":"Kaneko","year":"2020","journal-title":"Biochem. Biophys. Rep."},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0101","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","article-title":"CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers","volume":"80","author":"Kong","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2021.101079_bib0102","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.2147\/OTT.S247836","article-title":"Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0103","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201601012","article-title":"The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages","volume":"6","author":"Rios de la Rosa","year":"2017","journal-title":"Adv. Healthc. Mater."},{"issue":"11","key":"10.1016\/j.tranon.2021.101079_bib0104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143986","article-title":"Correction: differences in CD44 surface expression levels and function discriminates IL-17 and IFN-\u03b3 producing helper T cells","volume":"10","author":"Schumann","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.tranon.2021.101079_bib0105","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.tranon.2021.101079_bib0106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130416","article-title":"Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell","volume":"4","author":"He","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.tranon.2021.101079_bib0107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1058","article-title":"T cell killing does not require the formation of a stable mature immunological synapse","volume":"5","author":"Purbhoo","year":"2004","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2021.101079_bib0109","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.tranon.2021.101079_bib0110","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","article-title":"Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors","volume":"108","author":"Donnadieu","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.tranon.2021.101079_bib0111","series-title":"Robbins Basic Pathology E-Book","author":"Kumar","year":"2017"},{"issue":"3","key":"10.1016\/j.tranon.2021.101079_bib0112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2021.101079_bib0113","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"15","key":"10.1016\/j.tranon.2021.101079_bib0114","article-title":"Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101079_bib0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J. Cell. Immunother."},{"issue":"924","key":"10.1016\/j.tranon.2021.101079_bib116","article-title":"Strategies for dodging the obstacles in CAR T cell therapy","volume":"11","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2021.101079_bib117","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101079_bib118","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug. Discov."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:43:47Z","timestamp":1761835427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":118,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1936523321000711"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101079","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antigens of CAR T cell therapy: New roads; old destination","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101079"}}